Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay.
Berghen C, Albersen M, Blanchard P, Bossi A, Briganti A, Cozzarini C, Decaestecker K, Fonteyne V, Haustermans K, Joniau S, Lim Joon D, Khoo V, Nguyen PL, Ost P, Villeirs G, Vulsteke C, Zietman A, De Meerleer G. Berghen C, et al. Among authors: vulsteke c. BJU Int. 2019 Jul;124(1):35-39. doi: 10.1111/bju.14686. Epub 2019 Feb 20. BJU Int. 2019. PMID: 30680874 Review. No abstract available.
Malnutrition prevalence in cancer patients in Belgium: The ONCOCARE study.
Rasschaert M, Vandecandelaere P, Marechal S, D'hondt R, Vulsteke C, Mailleux M, De Roock W, Van Erps J, Himpe U, De Man M, Mertens G, Ysebaert D. Rasschaert M, et al. Among authors: vulsteke c. Support Care Cancer. 2024 Jan 27;32(2):135. doi: 10.1007/s00520-024-08324-6. Support Care Cancer. 2024. PMID: 38280135 Free PMC article.
Elective nodal radiotherapy in prostate cancer.
De Meerleer G, Berghen C, Briganti A, Vulsteke C, Murray J, Joniau S, Leliveld AM, Cozzarini C, Decaestecker K, Rans K, Fonteyne V, De Hertogh O, Bossi A. De Meerleer G, et al. Among authors: vulsteke c. Lancet Oncol. 2021 Aug;22(8):e348-e357. doi: 10.1016/S1470-2045(21)00242-4. Lancet Oncol. 2021. PMID: 34339655 Review.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Smith MR, et al. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. Lancet Oncol. 2022. PMID: 35131040 Free PMC article. Clinical Trial.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. González-Martín A, et al. Among authors: vulsteke c. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562799 Clinical Trial.
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Marth C, et al. Among authors: vulsteke c. Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19. Int J Gynecol Cancer. 2022. PMID: 34799418 Free PMC article.
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H. Vulsteke C, et al. Ann Oncol. 2013 Jun;24(6):1513-25. doi: 10.1093/annonc/mdt008. Epub 2013 Feb 7. Ann Oncol. 2013. PMID: 23396606 Free article.
48 results